First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
2021 · Journal of Thrombosis and Haemostasis · 79 citations
https://doi.org/10.1111/jth.15439
D
Dirk Thomas
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
23
Papers
656
Citations
13
h-index
14
i10-index
Dirk Thomas is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Pain Mechanisms and Treatments & Pharmacogenetics and Drug Metabolism & Pain Management and Opioid Use. The author has an h-index of 13, co-authored 20 publications.
ORCID: 0000-0002-0061-1632Papers by this author
worksBAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
2019 · Research and Practice in Thrombosis and Haemostasis · 76 citations
https://doi.org/10.1002/rth2.12186
Metabolism and Pharmacokinetic Drug–Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies
2020 · Clinical Pharmacokinetics · 55 citations
https://doi.org/10.1007/s40262-020-00895-x
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
2022 · Journal of Thrombosis and Haemostasis · 25 citations
https://doi.org/10.1111/jth.15744
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
2013 · BMC Pharmacology and Toxicology · 9 citations
https://doi.org/10.1186/2050-6511-14-s1-p5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat